Navigation Links
Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
Date:12/11/2009

OSLO, December 11 /PRNewswire-FirstCall/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind, randomized, controlled trial that enrols patients with CRPC and symptomatic bone metastases who will be randomized to receive Alpharadin (radium-223 chloride) plus best standard of care or placebo plus best standard of care. Approximately 750 patients are expected to be enrolled at more than 125 medical centers worldwide. Algeta expects to enroll patients across up to 15 sites in the US. Global recruitment remains on schedule and is expected to be complete by the second half of 2010.

The Principal Investigator of the ALSYMPCA study in the US is Dr. Oliver Sartor, Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine at the Tulane Cancer Center in New Orleans. The Tulane Cancer Center is one of the top cancer-focused medical centers in the US.

Dr. Sartor is an internationally recognized medical oncologist with an interest in prostate cancer from both a basic research and clinical perspective. He is chair-elect of the US Department of Defense Prostate Cancer Integration Panel and is co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Genitourinary Cancer Committee of the Radiation Oncology Treatment Group, a leading US multicenter research organization testing novel radiotherapy approaches against cancer.

Dr Sartor commented: "Alpharadin works by tar
'/>"/>

SOURCE Algeta
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Algeta Appoints Andrew Kay as President and Chief Executive Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Pittcon Organizing ... of Food Safety Tech , an e-Journal and producer ... an agreement for the second year for the co-location of ... 2014. The partnership provides that the registration fee to attend ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... On Thursday, December 9th, Mediaplanet published ... spearheading an industry-wide call to action advocating consumer ... us confront society,s most pressing challenges. By teaming ... Mediaplanet ,s ,Biotechnology, encourages appropriate policy action and ...
... China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: ... probiotics products in China, today announced that it has ... promissory notes for cash two days before the December ... notes were originally issued on December 11, 2007. The ...
... 8, 2010 Martek Biosciences Corporation (Nasdaq: MATK ... and fiscal year ended October 31, 2010. Total revenues for ... fourth quarter of fiscal 2009. Fourth quarter non-GAAP earnings per ... diluted share in last year,s fourth quarter.  For the full ...
Cached Biology Technology:The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 3Martek Announces Fourth Quarter and FY 2010 Financial Results 2Martek Announces Fourth Quarter and FY 2010 Financial Results 3Martek Announces Fourth Quarter and FY 2010 Financial Results 4Martek Announces Fourth Quarter and FY 2010 Financial Results 5Martek Announces Fourth Quarter and FY 2010 Financial Results 6Martek Announces Fourth Quarter and FY 2010 Financial Results 7Martek Announces Fourth Quarter and FY 2010 Financial Results 8Martek Announces Fourth Quarter and FY 2010 Financial Results 9Martek Announces Fourth Quarter and FY 2010 Financial Results 10Martek Announces Fourth Quarter and FY 2010 Financial Results 11Martek Announces Fourth Quarter and FY 2010 Financial Results 12
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
(Date:4/23/2014)... manufacturers are turning away from using triclosan as an ... health concerns. And now scientists are reporting new evidence ... in the ACS journal Chemical Research in Toxicology ... substance called octylphenol, promoted the growth of human breast ... in mice. , Kyung-Chul Choi and colleagues note that ...
(Date:4/23/2014)... to date of the family of bacteria that ... strategies and reveals surprising findings about the bacteria,s ... public health strategies to control this respiratory disease, ... Genomic analysis of 343 strains of the ... collected over the last 100 years illustrates how ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
... photographic filter (S37100, Photographic Filters for ... ideal for black-and-white photography of gels ... gel stain, the safer ethidium bromide ... photographic filter is identical to the ...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
LAL Chromogenic Endpoint assay...
Biology Products: